Equity grants give Kymera (KYMR) CMO 76,000 options and 38,000 RSUs
Rhea-AI Filing Summary
Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics, Inc. reported that Chief Medical Officer Terence Rooney received equity awards consisting of 76,000 stock options to buy common stock at $110.05 per share, expiring July 26, 2036, plus 38,000 restricted stock units. The RSUs vest in four equal annual installments following July 27, 2026, and the options vest 25% on July 27, 2027 with the remainder in 36 equal monthly installments, in each case subject to his continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 38,000 shares
Net Buy
2 txns
Insider
Rooney Terence
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 76,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 38,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 76,000 shares (Direct);
Common Stock — 38,000 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annualinstallments following July 27, 2026, subject to the reporting person's continued employment through each vesting date.
- F2. Twenty-five percent (25%) of the shares underlying this stock option shall vest on July 27, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.
Key Figures
Stock options granted: 76,000 shares
Option exercise price: $110.05 per share
Option expiration date: July 26, 2036
+4 more
7 metrics
Stock options granted
76,000 shares
Stock Option (Right to Buy) granted on July 27, 2026 to the CMO
Option exercise price
$110.05 per share
Exercise price of the 76,000 stock options granted to Terence Rooney
Option expiration date
July 26, 2036
Expiration date of the granted stock options
RSUs granted
38,000 units
Restricted stock units reported as an award on July 27, 2026
RSU vesting schedule
4 equal annual installments
RSUs vest in four equal annual installments following July 27, 2026
Initial option vesting
25% on July 27, 2027
First vesting tranche for the 76,000 stock options
Remaining option vesting
36 equal monthly installments
Balance of stock option award vests monthly after the initial 25% vesting
Key Terms
restricted stock units ("RSUs"), vesting, stock option, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting financial
"RSUs shall vest in four equal annual installments following July 27, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
stock option financial
"shares underlying this stock option shall vest on July 27, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "110.0500" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-07-26" for the granted stock options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Kymera (KYMR) report for Chief Medical Officer Terence Rooney?
Kymera reported equity grants to CMO Terence Rooney: 76,000 stock options and 38,000 restricted stock units. These are awards, not market purchases or sales, and increase his potential future ownership if vesting and exercise conditions are met.
How many stock options were granted to Kymera (KYMR) CMO Terence Rooney and at what price?
Terence Rooney received 76,000 stock options to buy Kymera common stock at an exercise price of $110.05 per share. The options expire on July 26, 2036, subject to the detailed vesting schedule disclosed.
What RSU awards were disclosed for Kymera (KYMR) CMO Terence Rooney?
Rooney was granted 38,000 restricted stock units (RSUs), each representing a contingent right to one Kymera common share. The RSUs vest in four equal annual installments following July 27, 2026, conditioned on his continued employment through each vesting date.
What is the vesting schedule for the new Kymera (KYMR) stock options granted to Terence Rooney?
The options vest 25% on July 27, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. Vesting for each tranche requires Rooney’s continued employment through the applicable vesting date.
Are Terence Rooney’s Kymera (KYMR) equity grants tied to a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. It characterizes these transactions as option and RSU awards rather than trades executed under a pre-arranged trading plan.